LIFE-CHANGING INNOVATIONS
Our Platform
Cureitec™ Platform
(VAXX’s proprietary AI/ML-based Innovation Engine)
A proprietary, decentralized AI/ML platform tailored for drug discovery and development, with a focus on Cell & Gene Therapy products. Our platform accelerates the development of novel RNA-based therapeutics, vaccines, and cell-based therapies, including innovative protein and antibody therapies. By integrating complex data mining, wet-lab experimentation, and state-of-the-art bioanalytical technologies, our solutions enhance research efficiency and cost-effectively boost productivity by 50-80% across diverse drug development pipelines at VAXX.
Cell Therapy :
Engineered Autologous HSCs
Vaxx’s cell therapy platform utilizes advanced AI-powered gene-modulating tools to modify CCR5 receptors in T4 lymphocyte cells. Our reversible and safe gene-editing method complements precision medicine. When paired with adoptive cell therapy and chemotherapy, it offers a promising potential cure for HIV infection.
Gene Therapy:
Nucleic acid-based Therapeutics and Vaccines
Vaxx employs its proprietary AI-driven DNA and RNA design, along with a non-viral delivery system, to create precision genetic medicine and therapeutic vaccines for better HIV prevention and management. This technology may also help develop cures for cancer, autoimmune disorders, and rare diseases.
Pipeline
At Vaxx Research Inc., our cutting-edge gene modulation and LNP delivery platform enables us to address a wide range of health challenges, from longevity to cancer to autoimmune diseases. With a focus on innovation and excellence, we are dedicated to advancing healthcare through groundbreaking biotechnologies.